Objectives: Effective treatment with direct-acting antiviral drugs against hepatitis C virus (HCV) is a medical need in cirrhotic HIV-HCV co-infected patients.
Methods: This study investigated the plasma levels of daclatasvir (DCV) and ribavirin (RBV) in HIV-HCV co-infected subjects treated with DCV, sofosbuvir, and RBV. Drug concentrations were quantified using validated high-performance liquid chromatography methods with ultraviolet detection. The HCV nonstructural protein 5A and non-structural protein 5B coding regions were analyzed by population-based sequencing. Results: DCV was dosed at week 4 and at week 8 of treatment, and RBV at week 8. One patient had the lowest DCV level, corresponding to 32.7% of the overall median value of the other patients at week 4 and about 40% at week 8. The Y93H variant was detected in this subject at weeks 8, 16, and 20 of treatment, but not before treatment or at day 2, and the patient experienced virological failure. Another subject with the Y93H variant at baseline and appropriate DCV levels had HCV RNA <12 IU/ml at week 12 and undetectable at week 16. Conclusions: Sub-optimal DCV drug levels allow the selection of resistance-associated variants and fail to contribute to antiviral activity. No definite reason for the low DCV level was found. Quantifying the drug is suggested in difficult-to-treat patients. 
Results
At the start of treatment with DAA, no naturally occurring resistance-associated variant (RAV) was found in six subjects; however the Y93H variant was found in one (patient 8). Six patients had undetectable HCV RNA at week 24. Patient 8 was still on therapy but with HCV RNA <12 IU/ml at week 12 and undetectable at week 16, while patient 6 continued to have detectable HCV RNA up to week 24. Patient 4 had consistently low levels of plasma HIV RNA; all of the other patients had HIV RNA fully suppressed throughout the study period.
DCV was dosed at week 4 and at week 8 of treatment, and RBV at week 8. Patient 6 had a DCV level corresponding to 32.7% of the overall median value of the other patients at week 4 and corresponding to 37.1% and 41% in two repeat controls at week 8 ( Table 2 ). The Y93H variant was identified in patient 6 at weeks 8, 16, and 20 of treatment, but not on day 2 of treatment. RBV levels were within the normal range in all seven patients tested. All patients had a 100% self-reported adherence to the treatment. Patient 6 was questioned regarding his adherence, but he confirmed taking the drugs in a timely manner each day; in keeping with this, his plasma HIV RNA was successfully suppressed.
Discussion
The relationship between the DCV plasma level and the role of the resistance mutant Y93H in determining the outcome of a regimen containing DCV is reported here . Two therapy time points were selected to monitor the bioavailability of DCV in HIV-HCVinfected patients (underexposure has been described previously for RBV). 4 The lowest DCV concentrations were observed in a subject who experienced virological failure (patient 6). Also patients 1 and 3 had low levels of DCV at week 4, but they reached higher concentrations at week 8; their better outcomes may relate to these different drug kinetics, or to the absence of 93H quasispecies, or to the activity of the other two components of the therapy. All patients had their successful HAART modified. These data underline the strong need to treat all co-infected patients regardless of the severity of liver fibrosis in order to avoid the risk of missing the chance to modify HAART in the case of resistance to antiretrovirals . For whatever reason, HCV RNA was always detectable in patient 6 and an NS5A resistance variant was identified at weeks 8, 16, and 20; NS5B sequences were not available due to the lower efficiency of the NS5A sequencing procedure at low HCV RNA copies. The patient's RBV plasma concentration was in the therapeutic range. Unfortunately, the patient's SOF plasma level was not measured and this is a limitation of the work. The failure to detect the Y93H mutant at baseline in patient 6 underlines the utility of deep sequencing to detect minor variants at baseline in difficult-to-treat subjects, such as HCV genotype 3 infected patients, to correctly address the therapeutic strategy. The Y93H substitution is reported to compromise the treatment with DCV, 5 to confer high-level resistance to DCV in genotype 3a patients, and to reduce the binding affinity of DCV to NS5A. 6 Patient 8 achieved HCV RNA suppression despite the presence of the Y93H mutation at baseline; of note, his DCV levels were DCV, daclatasvir; HCV, hepatitis C virus; NA, not available; N/AP, not applicable (patient was still on therapy and did not achieve the specific week); ND, not detectable; RAV, resistance-associated variant; RBV, ribavirin; UND, undetectable ( Lower limit of quantification 12 IU/ml). a Daclatasvir was tested twice in patient 6 at week 4 to confirm plasma levels and it was tested twice in seven of the eight patients at week 8 (all results reported, (a) and (b)). Patient 8 had no second daclatasvir determination at week 8 and no ribavirin dosing because no more samples were available. Resistance-associated variants at weeks 8, 16, and 20 are described as NS5A-related/NS5B-related. b IU/ml. c C trough , mg/ml. much higher than those found in patient 6. This result highlights the importance of residual drug activity even in the presence of RAVs and the importance of a therapeutic drug level to overcome the role of RAVs in determining therapeutic failure when present as either a minor or prevalent quasispecies. On the other hand, suboptimal drug levels allow the selection of RAVs and fail to contribute to antiviral activity, as seen in patient 6. However, other factors need to be taken into account, such as the baseline HCV plasma level, body mass index, interleukin 28 (IL28) genotype, and co-administered drug activity. 7 The HAART regimen of patient 6 was compatible with the anti-HCV therapy and no other drug with possible known interactions was co-administered, 8, 9 so no definite reason for his low DCV level was found. This suggests some difficulties in predicting DCV therapeutic levels in HIV-HCV-infected cirrhotic patients on HAART.
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